Sense Biodetection has completed a $50 million Series B financing, with the molecular diagnostics company saying it will use the proceeds to accelerate the launch of its Veros COVID-19 test, and further develop a portfolio of instrument-free, rapid molecular tests.
Those tests will be based on Sense’s Veros platform, which is designed to detect a variety of deadly and costly diseases by applying rapid molecular amplification technology.
The platform is intended to underpin a new class of rapid molecular diagnostic tests that emulate the performance of central laboratory PCR testing, but are disposable and easy-to-use since they do not need an accompanying instrument or reader.
As a result, Sense says, Veros diagnostics can be used beyond traditional healthcare settings–enabling better access, outcomes, and value for patients and providers.
